News | January 12, 2023
Merck completes tender offer to acquire Imago BioSciences
Merck intends to complete today the acquisition of Imago through a merger of Merck’s wholly owned subsidiary with and into Imago
Merck intends to complete today the acquisition of Imago through a merger of Merck’s wholly owned subsidiary with and into Imago
Acquisitions have the potential to add at least $1 billion in sales by 2028
MVUs will provide diagnosis treatment, vaccination, artificial insemination, minor surgical interventions, audio-visual aids and extension services to farmers/animal owners at their doorstep in far flung areas.
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
Lumpi-ProVacind is used for the prophylactic immunization of animals against Lumpy Skin Disease, which illicit protection for about one year
Centre and states need to work in tandem and in a collaborative spirit as was done during the previous surges for COVID-19 prevention and management
Miravo to remain a Canadian controlled and operated company following closing of the transaction
The investment will enable the company to enter European markets as well as enhance margins in current markets
As a result, Imago will become a subsidiary of Merck.
The proceeds of the issue has been/will be reinvested in the company and to meet its own business requirements.
Subscribe To Our Newsletter & Stay Updated
